221 related articles for article (PubMed ID: 16268979)
1. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Sugimura H; Hishida A; Ishizaki T
Aliment Pharmacol Ther; 2005 Nov; 22(10):1033-40. PubMed ID: 16268979
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study.
Kato S; Onda M; Matsukura N; Tokunaga A; Matsuda N; Yamashita K; Shields PG
Cancer; 1996 Apr; 77(8 Suppl):1654-61. PubMed ID: 8608558
[TBL] [Abstract][Full Text] [Related]
4. Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer.
Jainan W; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(24):10957-60. PubMed ID: 25605208
[TBL] [Abstract][Full Text] [Related]
5. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
[TBL] [Abstract][Full Text] [Related]
6. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
[TBL] [Abstract][Full Text] [Related]
7. Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese.
Sugimoto M; Furuta T; Shirai N; Kodaira C; Nishino M; Ikuma M; Sugimura H; Hishida A
Carcinogenesis; 2007 Sep; 28(9):2036-40. PubMed ID: 17389608
[TBL] [Abstract][Full Text] [Related]
8. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
9. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
He XX; Zhao YH; Hao YT
Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
[TBL] [Abstract][Full Text] [Related]
10. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer.
Lehmann DF; Medicis JJ; Franklin PD
J Clin Pharmacol; 2003 Dec; 43(12):1316-23. PubMed ID: 14615467
[TBL] [Abstract][Full Text] [Related]
13. [Interluekin-1 beta genetic polymorphism influences the impact of cytochrome P 2C19 genotype on the cure rate of H. pylori eradication therapy].
Mizuno M; Take S; Ishiki K; Okada H; Shiratori Y
Nihon Rinsho; 2004 Mar; 62(3):455-8. PubMed ID: 15038086
[TBL] [Abstract][Full Text] [Related]
14. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
16. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Sugimura H; Hishida A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1929-34. PubMed ID: 17035401
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
19. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.
Yamada S; Matsuhisa T; Makonkawkeyoon L; Chaidatch S; Kato S; Matsukura N
J Gastroenterol; 2006 Dec; 41(12):1169-77. PubMed ID: 17287896
[TBL] [Abstract][Full Text] [Related]
20. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
